( Bloomberg:AMBS@US,RICS:AMBS,ISIN:US02300U1060,OTC-BB:AMBS,OTC-QB:AMBS,OtherOTC:AMBS )

News from amarantus biosciences, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 07, 2016, 08:40 ET Amarantus Announces cGMP Manufacturing Readiness for Its Engineered Skin Substitute (ESS) Program at Lonza Walkersville

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and...


Jun 03, 2016, 09:00 ET Amarantus Completes Sale of Diagnostics Division, Announces Fiscal Year 2015 and First Quarter 2016 Financial Results

Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and...


May 27, 2016, 09:52 ET Amarantus Announces Upcoming Investor Presentations

Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and...


Apr 25, 2016, 08:00 ET Retired American Burn Association President Dr. David Ahrenholz to Present on Engineered Skin Substitute (ESS) at the Vatican's Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact

Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan...


Apr 21, 2016, 16:02 ET Amarantus Announces Capital Infusion

Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan...


Mar 22, 2016, 08:00 ET Amarantus Announces Cancellation of Special Meeting of Shareholders

Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and...


Mar 07, 2016, 15:30 ET Avant Diagnostics, Amarantus Diagnostics and Theranostics Health Provide Updated Information for Conference Call to Discuss Business Combination

Avant Diagnostics, Inc. (OTCQB: AVDX), a biotechnology company focused on the development of oncology based diagnostics, Amarantus Diagnostics,...


Mar 07, 2016, 08:53 ET Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health

Highlights of Business Combination  - Amarantus Diagnostics and Theranostics Health operations to consolidate into Avant Diagnostics...


Mar 04, 2016, 13:00 ET Amarantus Appoints Brian E. Harvey, MD PhD to Strategic Advisory Board

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and...


Feb 29, 2016, 07:30 ET Amarantus Receives Notices of Allowance from European Patent Office for MANF and CDNF in the Treatment of Retinal Disorders

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and...


Feb 22, 2016, 06:00 ET Amarantus and Lonza Walkersville, Inc. Provide Update on cGMP Manufacturing Readiness for the Engineered Skin Substitute (ESS) Program

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and...


Feb 19, 2016, 18:37 ET Amarantus Announces $3M Capital Infusion

Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan...


Feb 10, 2016, 07:45 ET Amarantus Receives Orphan Drug Designation From the US FDA for Eltoprazine in the Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and...


Feb 09, 2016, 14:23 ET Amarantus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and...


Feb 05, 2016, 08:30 ET Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and...


Feb 03, 2016, 09:00 ET Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and...


Jan 29, 2016, 09:00 ET Amarantus Announces Issuance of Chinese Patent Covering Use of MANF for the Treatment of Parkinson's Disease

Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan...


Jan 27, 2016, 15:30 ET Amarantus Announces $1M Investment

Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan...


Jan 19, 2016, 09:15 ET Amarantus Enters Into Letter of Intent to Merge Diagnostics Business Unit Into Avant Diagnostics

Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan...


Jan 15, 2016, 08:00 ET Amarantus to Present at ICV Sonoma Event

Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapies in Regenerative Medicine and Orphan disease, today...


Jan 11, 2016, 09:00 ET Amarantus to Present at SeeThruEquity First Annual Microcap Healthcare Investor Conference

Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing therapies in Regenerative Medicine and Orphan diseases,...


Dec 29, 2015, 08:00 ET Amarantus Requests Rare Pediatric Disease and Orphan Drug Designations from US FDA for Engineered Skin Substitute in the Treatment of Giant Congenital Melanocytic Nevi

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and...


Dec 22, 2015, 10:41 ET Amarantus Provides Update on cGMP Manufacturing Validation for the Engineered Skin Substitute (ESS) Program

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology...


Dec 16, 2015, 10:56 ET Amarantus Announces Peer-Reviewed Publication Further Describing Mechanisms of Action for Eltoprazine in the Treatment of Parkinson's LID

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and...


Dec 15, 2015, 07:30 ET Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Method of Treating Parkinson's Disease Levodopa-induced Dyskinesia (PD-LID)

  Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine,...